{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:33:01Z","timestamp":1793039581159,"version":"4.5.0"},"reference-count":137,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer is the seventh most commonly diagnosed cancer amongst women and has the highest mortality rate of all gynaecological malignancies. It is a heterogeneous disease attributed to one of three cell types found within the reproductive milieu: epithelial, stromal, and germ cell. Each histotype differs in etiology, pathogenesis, molecular biology, risk factors, and prognosis. Furthermore, the origin of ovarian cancer remains unclear, with ovarian involvement secondary to the contribution of other gynaecological tissues. Despite these complexities, the disease is often treated as a single entity, resulting in minimal improvement to survival rates since the introduction of platinum-based chemotherapy over 30 years ago. Despite concerted research efforts, ovarian cancer remains one of the most difficult cancers to detect and treat, which is in part due to the unique mode of its dissemination. Ovarian cancers tend to invade locally to neighbouring tissues by direct extension from the primary tumour, and passively to pelvic and distal organs within the peritoneal fluid or ascites as multicellular spheroids. Once at their target tissue, ovarian cancers, like most epithelial cancers including colorectal, melanoma, and breast, tend to invade as a cohesive unit in a process termed collective invasion, driven by specialized cells termed \u201cleader cells\u201d. Emerging evidence implicates leader cells as essential drivers of collective invasion and metastasis, identifying collective invasion and leader cells as a viable target for the management of metastatic disease. However, the development of targeted therapies specifically against this process and this subset of cells is lacking. Here, we review our understanding of metastasis, collective invasion, and the role of leader cells in ovarian cancer. We will discuss emerging research into the development of novel therapies targeting collective invasion and the leader cell population.<\/jats:p>","DOI":"10.3390\/ijms20061466","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T06:56:52Z","timestamp":1553497012000},"page":"1466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Therapeutic Targeting of Collective Invasion in Ovarian Cancer"],"prefix":"10.3390","volume":"20","author":[{"given":"Laura","family":"Moffitt","sequence":"first","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton VIC 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Karimnia","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton VIC 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2420-8458","authenticated-orcid":false,"given":"Andrew","family":"Stephens","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton VIC 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Bilandzic","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton VIC 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/ijc.22874","article-title":"Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum","volume":"121","author":"Kenny","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10585-004-5768-5","article-title":"Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers","volume":"21","author":"Burleson","year":"2004","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-5876-4-6","article-title":"Disaggregation and invasion of ovarian carcinoma ascites spheroids","volume":"4","author":"Burleson","year":"2006","journal-title":"J. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ijc.11086","article-title":"Cadherin switching in ovarian cancer progression","volume":"106","author":"Madan","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00428-006-0274-6","article-title":"Expression of E-cadherin transcriptional regulators in ovarian carcinoma","volume":"449","author":"Elloul","year":"2006","journal-title":"Virchows Arch"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12015-011-9344-5","article-title":"Overcoming challenges of ovarian cancer stem cells: Novel therapeutic approaches","volume":"8","author":"Rutledge","year":"2012","journal-title":"Stem Cell Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e84941","DOI":"10.1371\/journal.pone.0084941","article-title":"Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism","volume":"9","author":"Liao","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","article-title":"Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis","volume":"31","author":"Sodek","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","article-title":"Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis","volume":"309","author":"Yeung","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","article-title":"Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target","volume":"68","author":"Sawada","year":"2008","journal-title":"Cancer Res."},{"key":"ref_14","first-page":"3830","article-title":"Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H","volume":"53","author":"Cannistra","year":"1993","journal-title":"Cancer Res."},{"key":"ref_15","first-page":"1228","article-title":"In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: A novel role for CD44 in the process of peritoneal implantation","volume":"57","author":"Strobel","year":"1997","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1172\/JCI74778","article-title":"Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion","volume":"124","author":"Kenny","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","article-title":"Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids","volume":"159","author":"Casey","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/2159-8274.CD-11-0010","article-title":"Ovarian cancer spheroids use myosin-generated force to clear the mesothelium","volume":"1","author":"Iwanicki","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1593\/neo.08740","article-title":"Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer","volume":"10","author":"Landen","year":"2008","journal-title":"Neoplasia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-3163-6-11","article-title":"Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis","volume":"6","author":"Shield","year":"2007","journal-title":"J. Carcinog."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","article-title":"Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells","volume":"67","author":"Symowicz","year":"2007","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2005.08.005","article-title":"L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells","volume":"239","author":"Stoeck","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/0008-5472.CAN-05-1818","article-title":"Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody Treatment","volume":"66","author":"Arlt","year":"2006","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-06-1486","article-title":"Copper-67 Radioimmunotherapy and Growth Inhibition by Anti-L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis","volume":"13","author":"Knogler","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1541-7786.MCR-11-0256","article-title":"Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells","volume":"10","author":"Kim","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrm2720","article-title":"Collective cell migration in morphogenesis, regeneration and cancer","volume":"10","author":"Friedl","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1126\/science.1164073","article-title":"Morphogenetic Cell Movements: Diversity from Modular Mechanical Properties","volume":"322","author":"Montell","year":"2008","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrm.2015.14","article-title":"The front and rear of collective cell migration","volume":"17","author":"Mayor","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/pin.12391","article-title":"Collective invasion of cancer: Perspectives from pathology and development","volume":"66","author":"Wang","year":"2016","journal-title":"Pathol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ncb2548","article-title":"Classifying collective cancer cell invasion","volume":"14","author":"Friedl","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1261773","DOI":"10.1080\/21659087.2016.1261773","article-title":"Intravital characterization of tumor cell migration in pancreatic cancer","volume":"5","author":"Beerling","year":"2016","journal-title":"Intravital"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2159-8290.CD-14-0595","article-title":"Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO","volume":"5","author":"Sonoshita","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000450920","article-title":"Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin Expression","volume":"232","author":"Hesse","year":"2016","journal-title":"Dermatology"},{"key":"ref_34","first-page":"2125","article-title":"Collective cell movement in primary melanoma explants: Plasticity of cell-cell interaction, beta1-integrin function, and migration strategies","volume":"62","author":"Hegerfeldt","year":"2002","journal-title":"Cancer Res."},{"key":"ref_35","first-page":"2638","article-title":"Mammary collective cell migration involves transient loss of epithelial features and individual cell migration within the epithelium","volume":"125","author":"Ewald","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E854","DOI":"10.1073\/pnas.1508541113","article-title":"Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters","volume":"113","author":"Cheung","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.cell.2013.11.029","article-title":"Collective invasion in breast cancer requires a conserved basal epithelial program","volume":"155","author":"Cheung","year":"2013","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Haney, S., Konen, J., Marcus, A.I., and Bazhenov, M. (2018). The complex ecosystem in non small cell lung cancer invasion. PLoS Comput. Biol., 14.","DOI":"10.1371\/journal.pcbi.1006131"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1039\/c0ib00052c","article-title":"Determinants of leader cells in collective cell migration","volume":"2","author":"Khalil","year":"2010","journal-title":"Integr. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1073\/pnas.1120605109","article-title":"Three differentiation states risk-stratify bladder cancer into distinct subtypes","volume":"109","author":"Volkmer","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"a027854","DOI":"10.1101\/cshperspect.a027854","article-title":"Making Heads or Tails of It: Cell\u2013Cell Adhesion in Cellular and Supracellular Polarity in Collective Migration","volume":"9","author":"Venhuizen","year":"2017","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4161\/21541248.2014.989789","article-title":"Crossroads of PI3K and Rac pathways","volume":"6","author":"Campa","year":"2015","journal-title":"Small Gtpases"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ceb.2017.06.006","article-title":"Actomyosin contractility and collective migration: May the force be with you","volume":"48","author":"Pandya","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1071-5576(01)00122-8","article-title":"Composition of the Extracellular Matrix of the Peritoneum","volume":"8","author":"Witz","year":"2001","journal-title":"J. Soc. Gynecol. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"FEBS J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ijc.29464","article-title":"Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma","volume":"137","author":"Neri","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ncb3478","article-title":"A mechanically active heterotypic E-cadherin\/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion","volume":"19","author":"Labernadie","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ncb1658","article-title":"Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells","volume":"9","author":"Gaggioli","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11914","DOI":"10.1038\/ncomms11914","article-title":"KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis","volume":"7","author":"George","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Xiao-Lei, G., Wu, J.S., Cao, M.X., Gao, S.Y., Cen, X., Jiang, Y.P., Wang, S.S., Tang, Y.J., Chen, Q.M., and Liang, X.H. (2017). Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171341"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scr.2017.06.009","article-title":"solation and functional interrogation of adult human prostate epithelial stem cells at single cell resolution","volume":"23","author":"Hu","year":"2017","journal-title":"Stem Cell Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.stemcr.2017.07.004","article-title":"SOX2 Is a Marker for Stem-like Tumor Cells in Bladder Cancer","volume":"9","author":"Zhu","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrc2499","article-title":"Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions","volume":"8","author":"Visvader","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: Strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","article-title":"Metastasis: A question of life or death","volume":"6","author":"Mehlen","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.04.059","article-title":"Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer","volume":"149","author":"Matulonis","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Disis, M.L., Taylor, M.H., Kelly, K., Beck, J.T., Gordon, M., Moore, K.M., Patel, M.R., Chaves, J., Park, H., and Mita, A.C. (2019). Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2018.6258"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"LBA5007","DOI":"10.1200\/jco.2011.29.18_suppl.lba5007","article-title":"OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_60","first-page":"Cd007927","article-title":"Epidermal growth factor receptor blockers for the treatment of ovarian cancer","volume":"10","author":"Morrison","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: Past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging Biological Principles of Metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","article-title":"Epithelial Mesenchymal Transition in Tumor Metastasis","volume":"13","author":"Mittal","year":"2018","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.32607\/20758251-2015-7-2-17-28","article-title":"Cancer Invasion: Patterns and Mechanisms","volume":"7","author":"Krakhmal","year":"2015","journal-title":"Acta Nat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.celrep.2014.07.050","article-title":"Invadopodia Are Required for Cancer Cell Extravasation and Are a Therapeutic Target for Metastasis","volume":"8","author":"Leong","year":"2014","journal-title":"Cell Rep."},{"key":"ref_69","first-page":"599","article-title":"Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach","volume":"1846","author":"Trendowski","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_70","first-page":"1431","article-title":"Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma","volume":"50","author":"Bousquet","year":"1990","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/87.1.46","article-title":"Jasplakinolide\u2019s inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton","volume":"87","author":"Senderowicz","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Jalilian, I., Heu, C., Cheng, H., Freittag, H., Desouza, M., Stehn, J.R., Bryce, N.S., Whan, R.M., Hardeman, E.C., and Fath, T. (2015). Cell elasticity is regulated by the tropomyosin isoform composition of the actin cytoskeleton. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126214"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1158\/0008-5472.CAN-12-4501","article-title":"A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells","volume":"73","author":"Stehn","year":"2013","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbrc.2003.12.031","article-title":"Inhibition of pancreatic adenocarcinoma cellular invasiveness by blebbistatin: A novel myosin II inhibitor","volume":"313","author":"Duxbury","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mcn.2017.01.005","article-title":"The protein serine\/threonine phosphatases PP2A, PP1 and calcineurin: A triple threat in the regulation of the neuronal cytoskeleton","volume":"84","author":"Hoffman","year":"2017","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.trecan.2017.04.008","article-title":"Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges","volume":"3","author":"Gandalovicova","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e29710","DOI":"10.4161\/sgtp.29710","article-title":"Rho GTPases: Masters of cell migration","volume":"5","author":"Sadok","year":"2014","journal-title":"Small GTPases"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ncb2917","article-title":"Interplay of RhoA and mechanical forces in collective cell migration driven by leader cells","volume":"16","author":"Reffay","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"24187","DOI":"10.3390\/ijms141224187","article-title":"The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma","volume":"14","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1349-7006.2008.00977.x","article-title":"Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer","volume":"99","author":"Horiuchi","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3892\/or.2015.4009","article-title":"Knockdown of RhoA expression alters ovarian cancer biological behavior in vitro and in nude mice","volume":"34","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_82","first-page":"795","article-title":"KRT14 promoting invasion and migration of lung cancer cells through ROCK-1 signaling pathway","volume":"10","author":"Wang","year":"2017","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Martirosyan, A., Clendening, J.W., Goard, C.A., and Penn, L.Z. (2010). Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-103"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e12203","DOI":"10.7554\/eLife.12203","article-title":"Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis","volume":"5","author":"Mardakheh","year":"2016","journal-title":"eLife"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbapap.2005.06.015","article-title":"Development of specific Rho-kinase inhibitors and their clinical application","volume":"1754","author":"Tamura","year":"2005","journal-title":"BBA-Proteins Proteom."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4161\/cbt.9.11.11634","article-title":"Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo","volume":"9","author":"Deng","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1139\/Y10-047","article-title":"Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro","volume":"88","author":"Yang","year":"2010","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.biopha.2011.11.011","article-title":"The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer","volume":"66","author":"Yang","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"ref_89","first-page":"1221","article-title":"[Suppression of hepatocellular carcinoma invasion and metastasis by Rho-kinase inhibitor Fasudil through inhibition of BTBD7-ROCK2 signaling pathway]","volume":"39","author":"Hu","year":"2014","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eaai8504","DOI":"10.1126\/scitranslmed.aai8504","article-title":"Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis","volume":"9","author":"Vennin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/IGC.0b013e3181c03909","article-title":"Fasudil Inhibits Lysophosphatidic Acid-Induced Invasiveness of Human Ovarian Cancer Cells","volume":"19","author":"Ogata","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1038\/onc.2011.595","article-title":"The Rho\/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion","volume":"31","author":"Jeong","year":"2012","journal-title":"Oncogene"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4161\/cbt.13.1.18440","article-title":"Inhibition of the Rho\/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells","volume":"13","author":"Ohta","year":"2012","journal-title":"Cancer Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1158\/1078-0432.CCR-11-3313","article-title":"AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity","volume":"18","author":"Yap","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1200\/jco.2015.33.15_suppl.2566","article-title":"A first-in-human study of the dual ROCK I\/II inhibitor, AT13148, in patients with advanced cancers","volume":"33","author":"Kumar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1158\/0008-5472.CAN-05-0160","article-title":"Inhibition of Rho-Kinase Affects Astrocytoma Morphology, Motility, and Invasion through Activation of Rac1","volume":"65","author":"Salhia","year":"2005","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10585-011-9396-6","article-title":"RhoA\/ROCK signaling mediates plasticity of scirrhous gastric carcinoma motility","volume":"28","author":"Matsuoka","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00005-015-0382-6","article-title":"Novel Insights into the Roles of Rho Kinase in Cancer","volume":"64","author":"Wei","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","article-title":"Advances in targeting SRC in the treatment of breast cancer and other solid malignancies","volume":"16","author":"Mayer","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/gyno.2002.6851","article-title":"Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers","volume":"88","author":"Wiener","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"562","DOI":"10.18632\/oncotarget.301","article-title":"Targeting invadopodia to block breast cancer metastasis","volume":"2","author":"Eckert","year":"2011","journal-title":"Oncotarget"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-10-1432","article-title":"An EGFR\u2013Src\u2013Arg\u2013Cortactin Pathway Mediates Functional Maturation of Invadopodia and Breast Cancer Cell Invasion","volume":"71","author":"Mader","year":"2011","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"Steeg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ygyno.2012.06.009","article-title":"Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study","volume":"127","author":"Schilder","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2017.06.018","article-title":"A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma","volume":"83","author":"Vergote","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","article-title":"Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours","volume":"86","author":"Schoffski","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2011.08.033","article-title":"Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I\/II study of the Hoosier Oncology Group","volume":"123","author":"Ramasubbaiah","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute","volume":"4","author":"Hainsworth","year":"2015","journal-title":"Cancer Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/onc.2012.634","article-title":"Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities","volume":"33","author":"Patel","year":"2013","journal-title":"Oncogene"},{"key":"ref_113","unstructured":"ClinicalTrials.gov (2018, December 13). NCT00585052. A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients with Refractory or Relapsed Ovarian Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00585052."},{"key":"ref_114","unstructured":"ClinicalTrials.gov (2018, December 13). NCT02943317. Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination with Avelumab in Epithelial Ovarian Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02943317."},{"key":"ref_115","unstructured":"ClinicalTrials.gov (2018, December 13). NCT00671788. A Phase II Evaluation of Dasatinib (Sprycel\u00ae, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00671788."},{"key":"ref_116","unstructured":"ClinicalTrials.gov (2018, December 13). NCT00940225. Study of Cabozantinib (XL184) in Adults with Advanced Malignancies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00940225."},{"key":"ref_117","unstructured":"ClinicalTrials.gov (2018, December 13). NCT01716715. Cabozantinib or Paclitaxel in Treating Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01716715."},{"key":"ref_118","unstructured":"ClinicalTrials.gov (2018, December 13). NCT00093626. Sorafenib in Treating Patients with Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00093626."},{"key":"ref_119","unstructured":"ClinicalTrials.gov (2018, December 13). NCT00390611. Paclitaxel and Carboplatin with or without Sorafenib in the First-Line Treatment Of Patients With Ovarian Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00390611."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","article-title":"A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer","volume":"121","author":"Matthews","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_121","unstructured":"ClinicalTrials.gov (2019, February 25). NCT00516841: A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects with Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00516841."},{"key":"ref_122","unstructured":"ClinicalTrials.gov (2018, December 13). NCT01670799. Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01670799."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-15-0461","article-title":"A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients","volume":"21","author":"Guo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_124","unstructured":"ClinicalTrials.gov (2018, December 13). NCT02470299. Evaluation of GTPase Inhibition by Post-Operative Intravenous Ketorolac in Ovarian Cancer Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02470299."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"a004911","DOI":"10.1101\/cshperspect.a004911","article-title":"Basement Membranes: Cell Scaffoldings and Signaling Platforms","volume":"3","author":"Yurchenco","year":"2011","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","article-title":"Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study","volume":"14","author":"Ricart","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_127","first-page":"139","article-title":"CNTO 95, a fully human anti \u03b1v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells","volume":"25","author":"Chen","year":"2008","journal-title":"Off. J. Metastasis Res. Soc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","article-title":"A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma","volume":"105","author":"Pavlick","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or\u2014Dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kobayashi, M., Sawada, K., and Kimura, T. (2017). Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. Cancers, 9.","DOI":"10.3390\/cancers9070083"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","article-title":"Matrix metalloproteinases and tumor metastasis","volume":"25","author":"Deryugina","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_132","first-page":"8221","article-title":"Expression of Matrix Metalloproteinases in the Microenvironment of Spontaneous and Experimental Melanoma Metastases Reflects the Requirements for Tumor Formation","volume":"63","author":"Hofmann","year":"2003","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1242\/jcs.034561","article-title":"Matrix invasion by tumour cells: A focus on MT1-MMP trafficking to invadopodia","volume":"122","author":"Poincloux","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-08-3255","article-title":"Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis","volume":"69","author":"Devy","year":"2009","journal-title":"Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopha.2014.12.004","article-title":"Loss of RhoA expression prevents proliferation and metastasis of SPCA1 lung cancer cells in vitro","volume":"69","author":"Yang","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1038\/srep07656","article-title":"Leader cells regulate collective cell migration via Rac activation in the downstream signaling of integrin \u03b21 and PI3K","volume":"5","author":"Yamaguchi","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-15-0419","article-title":"R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis","volume":"14","author":"Guo","year":"2015","journal-title":"Mol. Cancer Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:40:06Z","timestamp":1760186406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":137,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["ijms20061466"],"URL":"https:\/\/doi.org\/10.3390\/ijms20061466","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]}}}